Guggenheim Capital LLC Has $720,000 Position in DaVita Inc. (NYSE:DVA)

Guggenheim Capital LLC lessened its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 33.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,813 shares of the company's stock after selling 2,419 shares during the quarter. Guggenheim Capital LLC's holdings in DaVita were worth $720,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in DVA. SBI Securities Co. Ltd. acquired a new position in shares of DaVita during the fourth quarter valued at $41,000. Canada Post Corp Registered Pension Plan bought a new position in DaVita in the 4th quarter worth about $55,000. Venturi Wealth Management LLC boosted its position in DaVita by 59.8% during the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after acquiring an additional 152 shares during the period. Versant Capital Management Inc increased its stake in DaVita by 58.7% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock valued at $68,000 after buying an additional 169 shares during the period. Finally, Blue Trust Inc. raised its holdings in DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock worth $76,000 after purchasing an additional 131 shares in the last quarter. Institutional investors own 90.12% of the company's stock.

DaVita Trading Up 0.1 %

Shares of NYSE:DVA traded up $0.18 during mid-day trading on Wednesday, hitting $141.72. The stock had a trading volume of 744,009 shares, compared to its average volume of 838,377. DaVita Inc. has a 12-month low of $131.27 and a 12-month high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The company has a market cap of $11.34 billion, a PE ratio of 13.20, a P/E/G ratio of 1.07 and a beta of 1.04. The company's 50 day moving average is $146.11 and its 200-day moving average is $154.92.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, sell-side analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analysts Forecast Growth

DVA has been the subject of a number of research reports. StockNews.com raised DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Cowen reiterated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Barclays raised their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.